Axsome: Q3 Earnings Snapshot – WTOP News
The Dutch healthcare company beat third-quarter profit forecasts as it set aside €288 million for a possible U.S. settlement tied to its sleep device recall.
- Axsome Therapeutics reported strong Q3 2026 results, with revenue accelerating behind AUVELITY's expansion into Alzheimer's disease agitation and depression, pushing the company to a $1 billion annualized revenue run-rate.
- Primary care adoption drove this expansion, as the total number of prescribers reached 77,000. With primary care now representing 40% of the base and 25% of prescriptions, the drug successfully reaches broader markets beyond specialists.
- Reported financial results included a narrowed net loss of $12.9 million. The quarter also saw $26.4 million in stock-based compensation expenses, reflecting the firm's ongoing investment in talent and commercial operations.
- Payer coverage remained robust at approximately 89% of total lives. This extensive network ensures broad access for patients across key depression and agitation indications, supporting the company's long-term commercial goals and patient reach.
- By May 1, 2027, the FDA is expected to reach a decision on AXS-12. The firm projects the treatment will eventually reach at least $8 billion in peak annual revenue across its approved indications.
163 Articles
163 Articles
AirBoss Reports 3rd Quarter 2026 Results
NEWMARKET, Ontario, Nov. 04, 2026 (GLOBE NEWSWIRE) -- AirBoss of America Corp. (TSX: BOS) (OTCQX: ABSSF) (the “Company” or “AirBoss”) today announced its third quarter 2026 results. The Company will host a conference call and webcast to discuss the results…
Zillow Group Reports Third-Quarter 2026 Financial Results
SEATTLE, Nov. 4, 2026 /PRNewswire/ -- Zillow Group, Inc. (NASDAQ: Z and ZG), which is transforming the way people buy, sell, rent and finance homes, today announced its consolidated financial results for the three months ended September 30, 2026.
Riot Platforms Soars 20% on Earnings and $28 Billion Corsicana AI Lease; Cipher Digital Plunges 13%, MARA Drops 5%
Riot Platforms just landed the biggest lease in its history while two of its closest crypto-miner rivals bled double digits in the same session, and the gap between them reveals exactly what the market is demanding before it rewards anyone else in this space.
Aprea Therapeutics Announces Third Quarter 2026 Financial Results
Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026) in Barcelona on November 20, 2026
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium































